Automated · AI-powered · Chip-based

Drug discovery,
re-created on a chip.

We design, manufacture, and automate microphysiological systems — bringing biology onto chips, and chips into the lab.

Licensed from A*STAR US patent granted >$1M SGD in grants
OncoMiMIC chip · injection-molded microfluidics
Licensed from A*STAR, Singapore Global CRO validation partnership Peer-reviewed in Bioeng. Transl. Med. Semiconductor-grade mass production
The problem

Preclinical drug discovery is slow, costly, and wrong too often.

~0%
of drug candidates fail in clinical trials
~$0B
average cost to bring one drug to market
1–2
endpoint metrics from standard 2D well-plate assays

Flat 2D assays and animal models fail to recapitulate the 3D tumor microenvironment. Cells on plastic inflate efficacy estimates, and the misses surface late — after hundreds of millions have already been spent. The industry needs data that is more relevant, more automated, and arrives earlier.

What we do

One capability stack. Three ways to work with us.

Microfluidic chip manufacturing, novel optics, robotic liquid handling, and AI computer vision. Our services are how we prove the stack works — and how the industry migrates toward it.

FLAGSHIP 01 · PLATFORM

OncoMiMIC Platform

Ex-vivo immuno-oncology on a chip. Recreate the 3D tumor microenvironment and measure immune recruitment, infiltration, and cytolytic kill — five or more readouts from a single run.

Explore OncoMiMIC →
02 · INTEGRATION

Systems Integration

We automate chip platforms end to end — imaging optics, robotic liquid handling, and AI-driven analysis — so your assays run hands-off, overnight, and reproducibly.

Automate your platform →
03 · SERVICES

Assay Migration & Consulting

Moving an in-vitro assay to chip format, or automating a chip platform you already run? We have done it from wafer to readout — and we will do it with you.

Start a conversation →
For investors

The case for Omni Biosystems

Market timing, traction, IP position, and the path from MVP chip to first revenue — everything you need to evaluate the opportunity, in one place.

Investor overview
Our capability stack

Four subsystems. Every product we build.

Each of our offerings draws on some combination of these four competencies. OncoMiMIC is what happens when all four are pointed at immuno-oncology.

Microfluidic chip manufacturing

Injection-molded, compartmentalized chips, mass-produced with semiconductor fabrication techniques.

TRL 5

Novel optics

Purpose-built imaging optics for live, longitudinal capture of cells inside the chip.

TRL 3

Robotic liquid handling

Automated dosing and cell loading for reproducible, hands-off experiment runs.

TRL 4

AI computer vision

Semantic segmentation, cell classification, and tracking that cuts read-out time by 5–20×.

TRL 4
The founding team

Operators and inventors who have done it before.

Nicholas Oh

Nicholas Oh

Chief Executive Officer
  • Founder & CEO, Enlitho Pte Ltd (est. 2017)
  • Raised >USD 2.5M in grants + private investment
  • 5× YoY revenue growth; ISO 9001 facility
  • Scaled ops to 1,000 wafers/month
  • BEng, SUTD (Magna Cum Laude)
Dr. Christopher Tostado

Dr. Christopher Tostado

Chief Scientific Officer
  • Inventor on the core US microfluidics patent
  • Sr. Research Scientist / PI, Genome Institute of Singapore
  • >$1M SGD in grant funding awarded
  • 15+ years microfluidics R&D
  • PhD Tsinghua · Dual BS, MIT
Hui Tang

Hui Tang

CFO / Business Development
  • Closed a USD 2M fundraise (2024)
  • Former CEO, Nufront (RMB 150M raise)
  • 27 patents in imaging & mobile tech
  • Cross-border BD: China, EU, US
  • Executive MBA, Erasmus / RSM
Get in touch

Bridging AI-driven discovery and clinical validation — for a world beyond animal testing.

Investors, pharma and CRO partners, researchers, and teams looking to move onto chips — we would love to hear from you. Reach us directly at contact@omni-biosystems.com.

Omni Biosystems Pte Ltd
Singapore
contact@omni-biosystems.com